* 150 mg dose strength of syn-004 was well tolerated by all
participants in this clinical trial
The post BRIEF-Synthetic Biologics announces positive topline results from second phase 2A clinical trial of SYN-004 appeared first on NASDAQ.
BRIEF-Synthetic Biologics announces positive topline results from second phase 2A clinical trial of SYN-004
